Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Enterprise Value of -$3.0 billion for Q1 2026, down 3.46% on a QoQ basis from -$2.9 billion in Q4 2025, and down 14.64% year-over-year from -$3.5 billion in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Enterprise Value (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$3.0 billion for Q1 2026.
- Quarterly Enterprise Value fell 14.64% year-over-year to -$3.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 billion (down 14.64% YoY) and the FY2025 annual result came in at -$2.9 billion, down 197.75% from the prior year.
- Enterprise Value was -$3.0 billion for Q1 2026 at Alnylam Pharmaceuticals, down from -$2.9 billion in the prior quarter.
- Across five years, Enterprise Value topped out at -$606.5 million in Q2 2022 and bottomed at -$3.0 billion in Q1 2026.
- A 5-year average of -$1.6 billion and a median of -$1.1 billion in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value slumped 405.73% — and 2023, when it surged 68.38%.
- Alnylam Pharmaceuticals' Enterprise Value stood at -$2.2 billion in 2022, then dropped by 12.08% to -$2.4 billion in 2023, then jumped by 59.77% to -$976.8 million in 2024, then tumbled by 197.75% to -$2.9 billion in 2025, then declined by 3.46% to -$3.0 billion in 2026.
- Business Quant data shows ALNY's Enterprise Value at -$3.0 billion in Q1 2026, -$2.9 billion in Q4 2025, and -$1.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -3.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.01 Bn |
| Dec 31, 2025 | -2.91 Bn |
| Sep 30, 2025 | -1.49 Bn |
| Jun 30, 2025 | -1.11 Bn |
| Mar 31, 2025 | -2.63 Bn |
| Dec 31, 2024 | -976.81 Mn |
| Sep 30, 2024 | -1.11 Bn |
| Jun 30, 2024 | -2.61 Bn |
| Mar 31, 2024 | -693.14 Mn |
| Dec 31, 2023 | -2.43 Bn |
| Sep 30, 2023 | -1.04 Bn |
| Jun 30, 2023 | -685.06 Mn |
| Mar 31, 2023 | -698.10 Mn |
| Dec 31, 2022 | -2.17 Bn |
| Sep 30, 2022 | -1.10 Bn |
| Jun 30, 2022 | -606.46 Mn |
| Mar 31, 2022 | -2.21 Bn |
| Dec 31, 2021 | -889.13 Mn |
| Sep 30, 2021 | -1.17 Bn |
| Jun 30, 2021 | -798.30 Mn |